3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Carcinoma, Hepatocellular
8
Nasopharyngeal Carcinoma
7
Esophageal Neoplasms
6
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Melanoma
4
Advanced NSCLC
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer
2
Leukemia, Myeloid, Acute
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Interventions
Bevacizumab
9
pembrolizumab
5
lenvatinib
5
durvalumab
5
atezolizumab
5
tremelimumab
3
fludarabine
3
camrelizumab
3
apatinib
3
Ipilimumab
3
Cyclophosphamide
3
regorafenib
2
Riluzole
2
Radiotherapy
2
Nivolumab
2
Magnetic Resonance Imaging
2
Idarubicin
2
Blood Specimen Collection
2
Biopsy
2
yttrium chloride
1
trastuzumab deruxtecan
1
spartalizumab
1
sintilimab
1
pertuzumab
1
ferric carboxymaltose
1
epigallocatechin gallate
1
donafenib
1
cemiplimab
1
brodalumab
1
Yttrium-90
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Liver Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05713994
2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
300 enrolled